Helyx Industries S.p.A. (BIT: HLX)
Health Care · Biotechnology · IT
€0.71
-3.51% today · -14.7% 1Y
Helyx Industries S.p.A. (BIT: HLX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $22.32M and employs 22 people.
Over the last twelve months the share price has lost 14.7%, trading between 0.56 and 1.40.
Tweenvest scores Helyx Industries S.p.A. across four factors: quality 38/100, value 68/100, growth 100/100. Its strongest factor is growth.
HLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $22.32M
- Revenue (TTM)
- $2.27M
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- €1.40
- 52-week low
- €0.56
- Avg volume (3M)
- —
- Shares outstanding
- 26.05M
- Employees
- 22
- Next earnings
- —
About Helyx Industries S.p.A.
Helyx Industries S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV. In addition, the company’s platforms also comprise NanoHybrid, a platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. The company was formerly known as Ulisse Biomed S.p.A. and change its name to Helyx Industries S.p.A. in December 2025. Helyx Industries S.p.A. was founded in 2015 and is based in Udine, Italy.
- Founded
- 2015
- Listed since
- Aug 3, 2021
- Exchange
- Borsa Italiana
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.